XtalPi Officially Included in HKEX Tech 100 Index, Reinforcing Its Position as a Hard-Tech Leader with Global Capital Recognition

Recently, the Hong Kong Stock Exchange officially launched the first Hong Kong stock technology index ——HKEX Tech 100 Index（HKEX Tech 100）XtalPi (2228.HK）As a benchmark enterprise in the AI pharmaceuticals field, XtalPi has been selected alongside tech giants such as Tencent, Alibaba, and CATL, joining the first tier of Hong Kong's technology sector. Following its inclusion and effectiveness in the MSCI China Index in November, this marks another authoritative recognition from the international capital market for XtalPi, further solidifying its leading position as a rare asset in the AI + robotics and AI for Science (technology empowerment) track.

Multiple Exponential Enhancements:

Scarcity and Growth Gain Global Capital Endorsement

The HKEX Tech 100 Index is the first flagship index in Hong Kong focusing on technological innovation, covering six cutting-edge fields including artificial intelligence, biomedicine, and robotics. All constituent stocks are eligible for Stock Connect, tracking the performance of the 100 largest technology companies listed on the Hong Kong Stock Exchange (HKEX) by market capitalization to provide investors with an efficient allocation tool for capturing investment opportunities in technology and emerging sectors. The index rigorously selects high-growth enterprises based on criteria such as R&D investment, innovation capability, and revenue growth rate, while setting a strict liquidity threshold of over HKD 20 million in average daily trading volume. Ultimately, only the top 100 emerging technology companies are included, offering investors in China and international markets an efficient tool for allocating core assets in hard tech.XtalPi's selection signifies that its technological value, platform scarcity, and commercialization capabilities have gained high recognition from the capital market.

As a leading company in the global AI pharmaceuticals field, XtalPi has reached cooperation with 17 of the top 20 global pharmaceutical companies, serving over 300 international enterprises and research institutions. Its business scope is rapidly extending from AI pharmaceuticals to new materials, energy, consumer goods, and other fields, accelerating the formation of its second growth curve. The inclusion in the index will directly bring incremental capital allocation — Hong Kong Exchanges and Clearing Limited has authorized E Fund Management to launch an ETF tracking this index, which is expected to attract more attention from domestic and international capital, bringing higher trading activity.

Performance Delivery:

Large Orders Validate Commercial Closed-Loop Capabilities

Looking Back at 2025: XtalPi's Commercialization Accelerates Significantly, High-Value Orders Validate Technology Conversion Capability. In August, the company reached a nearly $6 billion collaboration with U.S.-based DoveTree, setting a record for the largest order in the global AI pharmaceuticals field. An initial payment of $51 million has been received, with further payments and potential milestones amounting to $5.94 billion. In November, its wholly-owned subsidiary Ailux signed a $345 million bispecific antibody development platform agreement with Eli Lilly, marking the second collaboration between the two companies following a previous $250 million small-molecule drug partnership. This makes XtalPi one of the few platform enterprises covering both large and small molecule AI drug discovery. Additionally, the company’s self-developed consumer-grade anti-hair loss "Twin Star" ingredients Remeanagen™ and AquaKine™ have been successfully commercialized and registered with the U.S. FDA. As the patent holder, XtalPi will receive double-digit sales royalties, successfully leveraging its pharmaceutical-grade efficacy ingredient R&D platform to enter the consumer market, showcasing strong profit potential.

XtalPi's platform business model has clearly shifted “High Down Payment + Step-by-Step Milestones + Sales Revenue Sharing” The compound structure, with order value and long-term profitability continuing to rise, demonstrates a clear path of value growth.

Track Dividends:

AI for Science: A Trillion-Dollar Market Poised for Takeoff

The inclusion in the Hong Kong Stock Exchange Tech 100 Index further establishes XtalPi's leading position in the industrial-level AI application track.Reinforces its value as an "anchor asset" in the Hong Kong stock market's hard tech sector.From an industry perspective, the AI for Science track is experiencing explosive growth.XtalPi, as a benchmark and pioneer in this field, is redefining industry efficiency standards with its unique technology portfolio and extensive industry practice.

At the application level, XtalPi relies on itsA self-developed R&D platform that deeply integrates quantum physics, AI, and robotics experiments.An innovative R&D capability and business cooperation landscape covering biomedicine, new materials, agriculture, and new energy fields has been established. At the technical level,XtalPi has builtMore than 200 vertical field AI models, andThe automated high-throughput experimental cluster forms an iterative closed loop, which can effectively drive innovative breakthroughs and significantly shorten the R&D cycle. Currently, XtalPiMore than 6.5 million high-precision quantum chemical data have been independently generated, with a continuous accumulation of over 200,000 reaction data per month.PublicDepartmentMoreover, through real-world scenarios feeding back into technological evolution, a data moat is formed that competitors find hard to replicate.

On the strategic track of AI for Science, which represents future productivity, XtalPi has evolved from a technology explorer to an industry standard-setter. Its strategic approach of "platform-based output + global layout" will continue to drive industrial innovation and the transformation of achievements, creating value for investors.